Feasibility and outcome of repeat biopsy upon progression on tyrosine kinase inhibitors in patients with EGFR mutation positive adenocarcinoma of lung-an Indian tertiary cancer centre experience

被引：1
|
作者：
Zanwar, Saurabh
Noronha, Vanita
Joshi, Amit
Patil, Vijay Maruti
Chougule, Anuradha
Janu, Amit
Kumar, Rajiv
Prabhash, Kumar
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e20628
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20628
引用
收藏
页数：5
相关论文
共 50 条
  • [1] SIMILAR EFFICACY OF EGFR TYROSINE KINASE INHIBITORS REGARDLESS OF TREATMENT SEQUENCE FOR THE PATIENTS WITH EGFR MUTATION-POSITIVE PULMONARY ADENOCARCINOMA
    Koo, Dong Hoe
    Kim, Kyu-Pyo
    Choi, Chang-Min
    Lee, Dae-Ho
    Lee, Jae Cheol
    Lee, Jung-Shin
    Jang, Se Jin
    Kim, Sang-We
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S409 - S410
  • [2] Prevalence of Tissue EGFR Mutation in Patients of Adenocarcinoma Lung and Its Ability to Predict Response to Tyrosine Kinase Inhibitors
    Dhanuka, Ashutosh
    Mohan, Anant
    Guleria, Randeep
    Khilnani, Gopi
    Madan, Karan
    Hadda, Vijay
    Saxena, Alpana
    CHEST, 2016, 150 (04) : 724A - 724A
  • [3] Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma
    Tatsuya Yoshida
    Genichiro Ishii
    Koichi Goto
    Kiyotaka Yoh
    Seiji Niho
    Shigeki Umemura
    Shingo Matsumoto
    Hironobu Ohmatsu
    Kanji Nagai
    Yuichiro Ohe
    Atsushi Ochiai
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1691 - 1700
  • [4] Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma
    Yoshida, Tatsuya
    Ishii, Genichiro
    Goto, Koichi
    Yoh, Kiyotaka
    Niho, Seiji
    Umemura, Shigeki
    Matsumoto, Shingo
    Ohmatsu, Hironobu
    Nagai, Kanji
    Ohe, Yuichiro
    Ochiai, Atsushi
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (10) : 1691 - 1700
  • [5] EGFR mutation analysis and treatment outcomes with tyrosine kinase inhibitors in EGFR mutants: The Manchester Lung Cancer Group Experience.
    Peck, Rahul
    Connolly, Elizabeth
    Taylor, Paul
    Faivre-Finn, Corinne
    Blackhall, Fiona Hellen
    Wallace, Andrew
    Lee, Lip
    Bayman, Neil
    Burt, Paul
    Summers, Yvonne J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung
    Conforti, Fabio
    Catania, Chiara
    Toffalorio, Francesca
    Duca, Matteo
    Spitaleri, Gianluca
    Barberis, Massimo
    Noberasco, Cristina
    Delmonte, Angelo
    Santarpia, Mariacarmela
    Lazzari, Chiara
    De Pas, Tommaso Martino
    LUNG CANCER, 2013, 81 (03) : 440 - 444
  • [7] Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors
    Levy, Benjamin P.
    Rao, Parth
    Becker, Daniel J.
    Becker, Kevin
    ONCOLOGY-NEW YORK, 2016, 30 (07): : 601 - 612
  • [8] EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations
    Kim, Edward S.
    Melosky, Barbara
    Park, Keunchil
    Yamamoto, Nobuyuki
    Yang, James C-H
    FUTURE ONCOLOGY, 2021, 17 (18) : 2395 - 2408
  • [9] A single centre experience of gefitinib in patients with EGFR mutation positive non small cell lung cancer
    Walter, H. S.
    Fennell, D. A.
    Ahmed, S. I.
    LUNG CANCER, 2013, 79 : S7 - S7
  • [10] Biopsy on progression in patients with EGFR mutation-positive advanced non-small-cell lung cancer-a Canadian experience
    Chu, Q.
    Agha, A.
    Devost, N.
    Walton, R. N.
    Ghosh, S.
    Ho, C.
    CURRENT ONCOLOGY, 2020, 27 (01) : 27 - 33
12345